サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1634145

鎮痛剤の世界市場 - 2025～2032年

Global Analgesics Market - 2025 - 2032

出版日
ページ情報
英文 176 Pages
納期
即日から翌営業日
カスタマイズ可能
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.06円
鎮痛剤の世界市場 - 2025～2032年
出版日: 2025年01月13日
発行: DataM Intelligence
ページ情報: 英文 176 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

鎮痛剤の世界市場は2024年に560億2,000万米ドルに達し、2032年には805億米ドルに達すると予測され、予測期間2025年のCAGRは4.1%で成長する見込みです。

一般に鎮痛剤として知られる鎮痛剤は、痛みを和らげるために設計された薬剤クラスです。体内の痛みのシグナルをブロックしたり、脳がそのシグナルを解釈する方法を変えたりすることで効果を発揮します。これらの薬には、市販薬から処方薬まで様々な種類があります。これらの薬は、オーラル、非経口、局所的に服用することができます。

市場力学：

促進要因と阻害要因

慢性疼痛疾患の増加

慢性疼痛疾患の有病率の増加は、世界の鎮痛剤市場の重要な促進要因です。世界中の人口が高齢化するにつれて、関節炎、腰痛、糖尿病関連神経障害、線維筋痛症などの長期的な症状を抱える人が増えています。これらの慢性疼痛は、継続的な疼痛管理を必要とすることが多く、鎮痛剤の安定した需要につながっています。例えば、米国疾病予防管理センターによると、2021年には米国成人の推定20.9％（5,160万人）が慢性疼痛を経験し、6.9％（1,710万人）が影響の大きい慢性疼痛を経験しています。

未治療の痛みが長期的な影響を及ぼすという認識が高まるにつれ、医療による解決策を求める人が増え、鎮痛剤の需要を押し上げています。この動向は、特に北米や欧州のような新興国市場で顕著です。北米ではヘルスケアへのアクセスが普及しており、患者は慢性疾患の治療を求める傾向が強いです。例えば、2022年にScienceDirectが発行したジャーナルによると、痛みは一般的で持続的な症状であり、がん治療中の有病率は55%にも上ります。このため、鎮痛剤の使用と需要が増加し、市場全体の成長を促進すると予想されます。慢性疼痛の有病率が上昇を続ける中、世界の鎮痛剤市場は拡大が見込まれており、製薬会社はこのニーズの高まりに対応するため、より効果的で安全な新しい疼痛緩和オプションの開発に注力しています。

鎮痛剤に関連する副作用と安全性への懸念

鎮痛剤の長期使用による潜在的な副作用に対する意識の高まりは、鎮痛剤市場にとって重要な課題となっています。非ステロイド性抗炎症薬やオピオイドのような鎮痛剤に関連する副作用に対する認識が高まるにつれ、多くの人々が鎮痛剤の長期使用をためらうようになってきています。例えば、NSAIDsの長期使用は、消化管出血、腎臓障害、心臓疾患のリスク増加といった深刻な問題を引き起こす可能性があります。その結果、継続的な疼痛管理のためにこれらの薬剤を処方することになると、患者も医師も慎重になり、これらの薬剤の需要が減少する可能性があります。

本レポートの詳細について - サンプル資料請求

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

  • 影響要因
    • 促進要因
      • 慢性疼痛疾患の罹患率の増加
    • 抑制要因
      • 鎮痛剤に関連する副作用と安全性の懸念
    • 機会
    • 影響分析

第5章 産業分析

  • ポーターのファイブフォース分析
  • サプライチェーン分析
  • 価格分析
  • 特許分析
  • 規制分析
  • SWOT分析
  • アンメットニーズ

第6章 タイプ別

  • 非オピオイド鎮痛剤
  • オピオイド鎮痛剤
  • 複合鎮痛剤

第7章 痛みの種類別

  • 急性
  • 慢性

第8章 用途別

  • がんの痛み
  • 手術の痛み
  • 神経障害性疼痛
  • その他

第9章 投与経路別

  • オーラル
  • 局所
  • 非経口
  • その他

第10章 流通チャネル別

  • 小売薬局
  • 病院薬局
  • オンライン薬局

第11章 地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • スペイン
    • イタリア
    • その他欧州地域
  • 南米
    • ブラジル
    • アルゼンチン
    • その他南米
  • アジア太平洋地域
    • 中国
    • インド
    • 日本
    • 韓国
    • その他アジア太平洋地域
  • 中東・アフリカ

第12章 競合情勢

  • 競合シナリオ
  • 市況・シェア分析
  • M&A分析

第13章 企業プロファイル

  • Bayer AG
    • 会社概要
    • 製品ポートフォリオと概要
    • 財務概要
    • 主な発展
  • Teva Pharmaceuticals USA, Inc.
  • Dr. Reddy's Laboratories Ltd.
  • Hikma Pharmaceuticals PLC
  • Lupin
  • Cipla
  • Sanofi
  • AdvaCare Pharma
  • Wellona Pharma
  • Montage Laboratories Pvt. Ltd.

第14章 付録

第15章 米国問い合わせ

  • 話題の鎮痛剤マーケット
  • 世界の高血圧治療薬市場
目次
Product Code: PH8943

The global Analgesics market reached US$ 56.02 billion in 2024 and is expected to reach US$ 80.50 billion by 2032, growing at a CAGR of 4.1% during the forecast period 2025-2032.

Analgesics, commonly known as painkillers, are a class of drugs designed to relieve pain. They work by blocking pain signals in the body or by altering the way the brain interprets those signals. These medications come in various forms, ranging from over-the-counter to prescription medications. These medications can be taken orally, parenterally, and topically.

Market Dynamics: Drivers & Restraints

Increasing prevalence of chronic pain conditions

The increasing prevalence of chronic pain conditions is a significant driver for the global analgesics market. As populations around the world age, more people are living with long-term conditions such as arthritis, back pain, diabetes-related neuropathy, and fibromyalgia. These chronic pain conditions often require ongoing pain management, leading to a consistent demand for analgesics. For instance, according to the Centers for Disease Control and Prevention, in 2021 an estimated 20.9% of U.S. adults (51.6 million persons) experienced chronic pain, and 6.9% (17.1 million persons) experienced high-impact chronic pain.

As awareness of the long-term effects of untreated pain increases, more people are seeking medical solutions, pushing up the demand for analgesics. This trend is especially evident in developed markets like North America and Europe, where healthcare access is more widespread, and patients are more likely to seek treatment for chronic conditions. For instance, according to the journal published by ScienceDirect in 2022, pain is a prevalent and persistent symptom, with prevalence rates up to 55% during cancer treatment. This increases the use and demand for analgesics which is expected to drive the overall market growth. As the prevalence of chronic pain continues to rise, the global analgesics market is expected to expand, with pharmaceutical companies focused on developing new, more effective, and safer pain relief options to meet this growing need.

Adverse effects and safety concerns associated with Analgesics

The growing awareness of the potential side effects of long-term use of pain medications is becoming a significant challenge for the analgesics market. As people are becoming more aware of the side effects associated with painkillers, like NSAIDs and opioids, many are becoming more hesitant to rely on them for extended periods. For example, prolonged use of NSAIDs can lead to serious issues like gastrointestinal bleeding, kidney damage, and an increased risk of heart problems. As a result, both patients and doctors are becoming more cautious when it comes to prescribing these drugs for ongoing pain management, which can decrease demand for these medications.

For more details on this report - Request for Sample material

Segment Analysis

The global analgesics market is segmented based on type, pain type, application, route of administration, distribution channel, and region.

Type:

Non-opioid analgesics segment is expected to dominate the global analgesics market share

Non-opioid analgesics segment holds a significant position in the global analgesics market. Non-opioid analgesics are expected to dominate the analgesics market due to growing concerns over the risks associated with opioid use, including addiction, overdose, and long-term side effects. As the awareness of these dangers rises, both patients and healthcare providers are increasingly seeking safer alternatives for pain management. Non-opioid analgesics, such as nonsteroidal anti-inflammatory drugs (NSAIDs), acetaminophen, and certain antidepressants or anticonvulsants used for pain relief, offer effective solutions without the same level of risk that opioids carry.

Several companies are initiating studies on the efficacy and safety of non-opioid analgesic drugs, which are leading to the manufacture of highly efficient drugs. For instance, in July 2024, Vertex Pharmaceuticals Incorporated announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) submission for suzetrigine, an investigational, oral, selective NaV1.8 pain signal inhibitor to treat moderate-to-severe acute pain. Suzetrigine has the potential to be the first new class of medicine to treat acute pain in over twenty years.

Geographical Analysis

North America is expected to hold a significant position in the global analgesics market share

North America is expected to maintain a dominant position in the global analgesics market due to several key factors. One of the main reasons is the high demand for pain management solutions driven by a large population dealing with chronic conditions like arthritis, back pain, and migraines. According to the report by the Centers for Disease Control and Prevention in 2022, an estimated 6.1 million people ages 12 or older reported having an opioid use disorder (OUD). This usage of analgesics is expected to increase with the rising number of disorders in the region.

The U.S., in particular, has one of the highest rates of chronic pain conditions, with millions of individuals suffering from ailments like arthritis, back pain, and migraines. According to the report by the Centers for Disease Control and Prevention in 2024, it is stated that in 2022, the age-adjusted prevalence of diagnosed arthritis in adults was 18.9%. Women (21.5%) were more likely than men (16.1%) to have arthritis. This creates a consistently high demand for pain relief products. Additionally, North America has a robust healthcare system with wide access to medications, making it easier for patients to seek treatment. The region's advanced pharmaceutical research and development capabilities also play a crucial role in the creation of new and more effective analgesics, whether for acute or chronic pain.

The presence of a large number of pharmaceutical companies also contributes to the overall region's market growth. These companies invest heavily in the development of next-generation pain medications, including non-opioid alternatives, in response to the ongoing opioid crisis. For instance, in October 2024, Protega Pharmaceuticals announced that the FDA granted regulatory approval to their oxycodone hydrochloride immediate-release (IR) CII 10 mg tablets (Roxybond) for the management of severe pain that requires an opioid analgesic for which alternative treatments are insufficient, according to a news release from the company. This focus on developing safer, more effective pain management solutions is expected to hold the region in the dominant position.

Competitive Landscape

The major global players in the analgesics market include Bayer AG, Teva Pharmaceuticals USA, Inc., Dr. Reddy's Laboratories Ltd., Hikma Pharmaceuticals PLC, Lupin, Cipla, Sanofi, AdvaCare Pharma, Wellona Pharma, and Montage Laboratories Pvt. Ltd. among others.

Key Developments

  • In February 2024, Hikma Pharmaceuticals PLC (Hikma) announced the launch of COMBOGESIC IV (acetaminophen and ibuprofen) injection in the US. COMBOGESIC IV is an intravenous, opioid-free pain relief medicine that is a combination of 1,000 mg of acetaminophen and 300 mg of ibuprofen, a nonsteroidal anti-inflammatory drug (NSAID).
  • In September 2024, Mankind Pharma's consumer business division introduced Nimulid Strong, a gel and spray formulation to address neck pain, a condition that impacts overall body function. With this launch, Mankind Pharma has entered the topical analgesic market.

Why Purchase the Report?

  • Pipeline & Innovations: Reviews ongoing clinical trials, and product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
  • Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
  • Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
  • Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
  • Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
  • Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
  • Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
  • Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
  • Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
  • Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
  • Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
  • Post-market Surveillance: Uses post-market data to enhance product safety and access.
  • Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The Global Analgesics market report delivers a detailed analysis with 60+ key tables, more than 50 visually impactful figures, and 176 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2023

  • Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
  • Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
  • Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
  • Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
  • Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
  • Supply Chain: Distribution and Supply Chain Managers.
  • Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
  • Academic & Research: Academic Institutions.

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Type
  • 3.2. Snippet by Pain Type
  • 3.3. Snippet by Application
  • 3.4. Snippet by Route of Administration
  • 3.5. Snippet by Distribution Channel
  • 3.6. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Increasing prevalence of chronic pain conditions
    • 4.1.2. Restraints
      • 4.1.2.1. Adverse effects and safety concerns associated with Analgesics
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Force Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Patent Analysis
  • 5.5. Regulatory Analysis
  • 5.6. SWOT Analysis
  • 5.7. Unmet Needs

6. By Type

  • 6.1. Introduction
    • 6.1.1. Analysis and Y-o-Y Growth Analysis (%), By Type
    • 6.1.2. Market Attractiveness Index, By Type
  • 6.2. Non-opioid Analgesics*
    • 6.2.1. Introduction
    • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 6.3. Opioid Analgesics
  • 6.4. Compound Analgesics

7. By Pain Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Pain Type
    • 7.1.2. Market Attractiveness Index, By Pain Type
  • 7.2. Acute*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Chronic

8. By Application

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.1.2. Market Attractiveness Index, By Application
  • 8.2. Cancer Pain*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Surgical pain
  • 8.4. Neuropathic Pain
  • 8.5. Others

9. By Route of administration

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of administration
    • 9.1.2. Market Attractiveness Index, By Route of administration
  • 9.2. Oral*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. Topical
  • 9.4. Parenteral
  • 9.5. Others

10. By Distribution Channel

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.1.2. Market Attractiveness Index, By Distribution Channel
  • 10.2. Retail Pharmacies*
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 10.3. Hospital Pharmacies
  • 10.4. Online Pharmacies

11. By Region

  • 11.1. Introduction
    • 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 11.1.2. Market Attractiveness Index, By Region
  • 11.2. North America
    • 11.2.1. Introduction
    • 11.2.2. Key Region-Specific Dynamics
    • 11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Pain Type
    • 11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.2.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.2.8.1. U.S.
      • 11.2.8.2. Canada
      • 11.2.8.3. Mexico
  • 11.3. Europe
    • 11.3.1. Introduction
    • 11.3.2. Key Region-Specific Dynamics
    • 11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Pain Type
    • 11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.3.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.3.8.1. Germany
      • 11.3.8.2. U.K.
      • 11.3.8.3. France
      • 11.3.8.4. Spain
      • 11.3.8.5. Italy
      • 11.3.8.6. Rest of Europe
  • 11.4. South America
    • 11.4.1. Introduction
    • 11.4.2. Key Region-Specific Dynamics
    • 11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Pain Type
    • 11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.4.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.4.8.1. Brazil
      • 11.4.8.2. Argentina
      • 11.4.8.3. Rest of South America
  • 11.5. Asia-Pacific
    • 11.5.1. Introduction
    • 11.5.2. Key Region-Specific Dynamics
    • 11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Pain Type
    • 11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.5.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.5.8.1. China
      • 11.5.8.2. India
      • 11.5.8.3. Japan
      • 11.5.8.4. South Korea
      • 11.5.8.5. Rest of Asia-Pacific
  • 11.6. Middle East and Africa
    • 11.6.1. Introduction
    • 11.6.2. Key Region-Specific Dynamics
    • 11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Pain Type
    • 11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.6.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

12. Competitive Landscape

  • 12.1. Competitive Scenario
  • 12.2. Market Positioning/Share Analysis
  • 12.3. Mergers and Acquisitions Analysis

13. Company Profiles

  • 13.1. Bayer AG*
    • 13.1.1. Company Overview
    • 13.1.2. Product Portfolio and Description
    • 13.1.3. Financial Overview
    • 13.1.4. Key Developments
  • 13.2. Teva Pharmaceuticals USA, Inc.
  • 13.3. Dr. Reddy's Laboratories Ltd.
  • 13.4. Hikma Pharmaceuticals PLC
  • 13.5. Lupin
  • 13.6. Cipla
  • 13.7. Sanofi
  • 13.8. AdvaCare Pharma
  • 13.9. Wellona Pharma
  • 13.10. Montage Laboratories Pvt. Ltd.

LIST NOT EXHAUSTIVE

14. Appendix

  • 14.1. About Us and Services

15. Contact Us

Suggestions for Related Report

  • Topical Analgesics Market
  • Global Anti-Hypertension Drugs Market

For more pharmaceuticals-related reports, please click here